Asset Management One Co. Ltd. decreased its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 27.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,745 shares of the company's stock after selling 4,489 shares during the period. Asset Management One Co. Ltd.'s holdings in Encompass Health were worth $1,099,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the company. State Street Corp grew its position in shares of Encompass Health by 0.7% during the third quarter. State Street Corp now owns 3,025,769 shares of the company's stock valued at $292,410,000 after purchasing an additional 21,329 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Encompass Health by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company's stock valued at $161,781,000 after acquiring an additional 20,547 shares during the last quarter. Copeland Capital Management LLC lifted its holdings in shares of Encompass Health by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,293,098 shares of the company's stock valued at $119,418,000 after acquiring an additional 8,548 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Encompass Health by 2,458.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company's stock valued at $83,990,000 after acquiring an additional 835,135 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Encompass Health by 0.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 769,716 shares of the company's stock valued at $71,083,000 after acquiring an additional 2,904 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.
A number of research analysts recently commented on EHC shares. Barclays increased their price target on shares of Encompass Health from $116.00 to $118.00 and gave the company an "overweight" rating in a report on Friday, February 7th. StockNews.com raised shares of Encompass Health from a "hold" rating to a "buy" rating in a report on Saturday, February 15th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $110.00 price target on shares of Encompass Health in a report on Tuesday, February 11th. KeyCorp raised their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Finally, Truist Financial reissued a "buy" rating and issued a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $107.67.
Check Out Our Latest Stock Report on EHC
In related news, CAO Andrew L. Price sold 5,042 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now owns 69,164 shares of the company's stock, valued at $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.10% of the company's stock.
Shares of NYSE:EHC traded down $2.47 during trading on Friday, reaching $97.42. 791,510 shares of the company were exchanged, compared to its average volume of 660,824. The firm has a market capitalization of $9.81 billion, a PE ratio of 21.84, a P/E/G ratio of 2.35 and a beta of 0.90. The business's fifty day simple moving average is $96.00 and its 200-day simple moving average is $95.76. Encompass Health Co. has a 12-month low of $73.68 and a 12-month high of $104.55. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04.
Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. On average, research analysts anticipate that Encompass Health Co. will post 4.8 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date of this dividend is Tuesday, April 1st. Encompass Health's dividend payout ratio (DPR) is presently 15.25%.
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.